Quoin Pharmaceuticals Receives U.S. Notice of Allowance for Patent Covering Combination Treatment for Netherton Syndrome

Patent ExpiryapprovedPositive

AI Analysis

Summary

Quoin Pharmaceuticals received a U.S. Notice of Allowance for a patent covering a combination treatment for Netherton Syndrome, strengthening the company's intellectual property position in this rare disease area.

Outcome Details

U.S. Notice of Allowance for patent covering combination treatment for Netherton Syndrome

Importance:4/10

Sentiment:

0.60

patentNetherton Syndromeintellectual property

Related Companies

$QNRX

Read the original article

Published by yahoo_finance on June 30, 2026 12:30 PM

Read Original